Research and development company Medlab Clinical has taken its first delivery of its cannabis-based medicine NanaBis from manufacturer Tasmanian Alkaloids (TasAlk).

A deal was struck between the two in January for TasAlk to handle production and analysis in a bid to increase supply and improve product quality and compliance. 

Medlab CEO Dr Sean Hall said the successful completion of a phase two advanced cancer pain trial at Royal North Shore Hospital had helped fuel demand for NanaBis.

He added: “Being able to partner with TasAlk is very exciting and allows Medlab to increase production capacities drastically over the short-term and therefore to meet increased demand.”

Revenue for NanaBis increased by 26% in Q1 2020 compared to the previous quarter with more than 2,000 bottles dispensed.